Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Share-based Liabilities Paid
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Share-based Liabilities Paid of $5.90 million for the 12-month period ending 2023-09-30, per its 10-K filed 2025-11-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Additional Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid · last filed 2025-11-17
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, equity instruments other than options, share-based liabilities paid for fiscal 2023 was $5.90M, a 28.26% increase from fiscal 2022.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, equity instruments other than options, share-based liabilities paid for fiscal 2022 was $4.60M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Share-based Liabilities Paid 12 month |
|---|---|
| 2023-09-30 | $5.90M 10-K · filed 2025-11-17 |
| 2022-09-30 | $4.60M 10-K · filed 2023-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |